

Neurofibromatosis type 1 (NF1)

Identity

Other names Von Recklinghausen neurofibromatosis
Peripheral neurofibromatosis

Inheritance autosomal dominant with almost complete penetrance; frequency is 30/10⁵ newborns (and 1 of 200 mentally handicapped persons): one of the most frequent genetically inheritable disease; neomutation in 50%, mostly from the paternal allele; highly variable expressivity, from very mild to very severe; expressivity is also age-related

Clinics

Note NF1 is an hamartoneoplastic syndrome; hamartomas are localized tissue proliferations with faulty differentiation and mixture of component tissues; they are heritable malformations that have a potential towards neoplasia; the embryonic origin of dysgenetic tissues involved in NF1 is ectoblastic.

Phenotype and clinics Diagnosis is made on the ground of at least 2 of the following:
café-au-lait spots (no 6 or more with 0.5 cm of diameter (in pre-puberty))
2 neurofibromas or 1 plexiform neurofibromas (mainly cutaneous)
2 Lisch nodules (melanocytic hamartomas of the iris)
freckling in the axillary/inguinal region (Crowe's sign)
glioma of the optic nerve
distinctive bone anomalies (scoliosis, pseudoarthroses, bony defects (orbital wall) ...)
positive family history

Other features:

macrocephaly
epilepsy
mental retardation in 10 %; learning disabilities in half patients
sexual precocity and other endocrine anomalies
hypertension (renal artery stenosis)

Neoplastic risk 5% of NF1 patients experience a malignant neoplasm
neurofibromas, especially the plexiform variety; polyclonal (benign) proliferation; may be present at birth or appear later, may be a few or thousands, small or enormous, occur in the skin and in various tissues and organs; neurofibromas localized to the spine are extremely difficult to manage.
neurofibrosarcomatous transformation (malignant) of these in 5-10 %
optic nerve gliomas

[childhood MDS](#) (myelodysplasia) and ANLL, often with monosomy 7 (monosomy 7 syndrome, 'juvenile myelomonocytic leukaemia'): risk, increased by X 200 to 500, is still low, as JMML is rare ; M>F; most often before the age of 5 yrs; no increased risk of leukaemia in the adult.

[pheochromocytomas](#)

various other neoplasias, of which are [rhabdomyosarcomas](#)

Treatment early diagnosis, lifetime monitoring and surgery are essential

Cytogenetics

Inborn conditions no special feature

Cytogenetics of cancer according to the cancer type in most cases
JMML : monosomy 7

Genes involved and Proteins

Gene Name [NF1](#)

Location 17q11.2

Protein

Description the protein has been called neurofibromin; GTPase activating protein (GAP) ; tumour suppressor.

Mutations

Germinal mainly nucleotide substitutions (splicing defects, nonsense mutations, missense mutations) and frameshift alterations, microdeletions (5-10%), some intragenic copy number changes on one allele

Somatic the second allele is often lost in the neoplastic cell owing to copy number loss and mitotic recombination events, but also minor lesion mutations are found

External links

[GeneCards](#) [NF1](#)

[GDB](#) [NF1](#)

[OMIM](#) [162200](#)

[Orphanet](#) [Neurofibromatosis type 1](#)

[HGMD](#) [120231](#)

Other database [Neurofibromatosis Type 1 - GeneClinics](#)

Association [Neurofibromatosis](#)

Bibliography

A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity.

Huson SM, Compston DA, Clark P, Harper PS.
J Med Genet 1989 Nov; 26(11): 704-711.
Medline [90064452](#)

Chromosome pattern in juvenile chronic myelogenous leukemia, myelodysplastic syndrome, and acute leukemia associated with neurofibromatosis.

Kaneko Y, Maseki N, Sakurai M, Shibuya A, Shinohara T, Fujimoto T, Kanno H, Nishikawa A.
Leukemia 1989 Jan; 3(1): 36-41.
Medline [89082060](#)

Genetic and epigenetic mechanisms in the pathogenesis of neurofibromatosis type I.

Metheny LJ, Cappione AJ, Skuse GR.
J Neuropathol Exp Neurol 1995 Nov; 54(6): 753-760.
Medline [96067328](#)

The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.

Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, Rubenstein A, Viskochil D.
JAMA 1997 Jul 2; 278(1): 51-57.
Medline [97350963](#)

Elevated risk for MPNST in NF1 microdeletion patients.

De Raedt T, Brems H, Wolkenstein P, Vidaud D, Pilotti S, Perrone F, Mautner V, Frahm S, Sciot R, Legius E.
Am J Hum Genet 2003 May; 72(5): 1288-1292.
Medline [12660952](#)

[REVIEW articles](#)

automatic search in PubMed

[Last year publications](#)

automatic search in PubMed

Contributor(s)

Written 09- Jean-Loup Huret

Updated 1997
02- Katharina Wimmer
2006

Citation

This paper should be referenced as such :

Huret JL . Neurofibromatosis type 1 (NF1). Atlas Genet Cytogenet Oncol Haematol. September 1997 .

URL : <http://AtlasGeneticsOncology.org/Kprones/NF1ID10006.html>

Wimmer K . Neurofibromatosis type 1 (NF1). Atlas Genet Cytogenet Oncol Haematol. February 2006 .

URL : <http://AtlasGeneticsOncology.org/Kprones/NF1ID10006.html>

© *Atlas of Genetics and Cytogenetics in Oncology and Haematology*
